Advertisement

Topics

HARVEY NASH GROUP Company Profile

18:35 EST 14th December 2018 | BioPortfolio

Harvey Nash was founded in London in 1988. David Higgins, the current Executive Vice Chairman, was one of the original founders and still has a sizeable financial stake in the company. Early on, the management broadened the Group’s geographical coverage and increased the range of services, recognising the value this would add to the business in the longer term.

An IPO in April 1997 facilitated a fresh injection of capital into the business, fast tracking expansion into Europe, the USA and Asia. This was achieved through a mix of acquisitions and organic growth.

Today, Harvey Nash holds a unique position as the only truly global IT recruitment business listed on the London Stock Exchange with over 3,000 employees and contractors working across 28 offices worldwide

Location

13 Bruton Street
London
London
W1J 6QA
United Kingdom

Contact

Phone: 44 (0)20 7333 0033
Fax: 44 (0)20 7333 0032
Email: info@harveynash.com


News Articles [1022 Associated News Articles listed on BioPortfolio]

Según la encuesta Harvey Nash/KPMG CIO, los directorios de empresas se apresuran a aumentar ...

- Las amenazas de ciberdelitos alcanzan su máximo histórico - Solo un quinto de los líderes de TI del mundo están bien preparados para un Read more...

Data and Cybersecurity Investments Ramp Up as Threats Reach All-Time High

Rajiv LeventhalCompanies are quickly ramping up investment in data and cybersecurity as they look to become more compliant with new data privacy protection and security regulations—and to avoid high...

What Have We Learned From Hurricane Harvey? One Year Later

Lessons learned from Hurricane Harvey: Dr. Neil Gandhi discusses management, medication access, and mental health issues. Medscape Emergency Medicine

CM Capital: Mark Harvey shares his views on the best type of scenario for financing a company and why he is optomistic for the future.

In this episode of PharmaTelevision News Review, Fintan Walton talks to Mark Harvey, Partner of CM Capital.

Hope and Challenges Remain One-Year After Hurricane Harvey Devastates the Coastal Bend

SINTON, Texas, Aug. 20, 2018 /PRNewswire/ -- One year ago on Aug. 25, Category Four Hurricane Harvey slammed into the Texas Gulf Coast. The last Read more...

Is NASH Really a $35 Billion Opportunity?

Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize? For the last few years, investors have been talking up the huge potential of drugs to treat nonalc...

Fecal bacteria contaminated surface water after Hurricane Harvey

Research by a civil and environmental engineering professor has substantiated that Hurricane Harvey caused high levels of fecal contamination to be introduced into waterways draining into the Gulf of ...

INVENTIVA: Inventiva launches an independent working group to help increase NASH awareness and establish best practices for its treatment

Inventiva launches an independent working group to help increase NASH awareness and establish best practices for its treatment Daix (France), September 24th, 2018 - Inventiva S.A. ("Inventiva" or ...

PubMed Articles [1885 Associated PubMed Articles listed on BioPortfolio]

Treatment of NASH with Gastric Bypass.

Nonalcoholic steatohepatitis (NASH) is a spectrum of nonalcoholic fatty liver disease (NAFLD). It is defined as the presence of fatty liver along with inflammation and hepatocyte injury. To date, weig...

Burden of Illness and Economic Model for Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States.

Non-alcoholic steatohepatitis (NASH) is the progressive form of non-alcoholic fatty liver disease (NAFLD). Our aim was to estimate the total economic burden of NASH and advanced NASH in the United Sta...

Models.

A look at the history of science supports this statement. Harvey's discovery of the blood circulation, published in 1628, is undoubtedly among the most important events in the history of physiology. A...

The future R&D landscape in non-alcoholic steatohepatitis (NASH).

Nonalcoholic steatohepatitis (NASH) is emerging as a major public health issue for the 21st century and is associated with significant liver-related morbidity and mortality. At present, there are no a...

Long-term effect of bariatric surgery on resolution of nonalcoholic steatohepatitis (NASH): An external validation and application of a clinical NASH score.

Nonalcoholic steatohepatitis (NASH) is an important etiology of end-stage liver disease. Long-term effect of bariatric surgery in improvement of NASH is not clear.

Clinical Trials [4288 Associated Clinical Trials listed on BioPortfolio]

Phase 1 Pharmacokinetic Study Of CP-945598 In Patients With NASH

CP-945598 is a potent and selective Cannabinoid-1 (CB1) receptor antagonist currently being developed for the treatment of obesity. CP-945598 is also being considered as a potential treat...

Different Doses of BI 1467335 Compared to Placebo in Patients With Clinical Evidence of NASH

The primary objective of this study is the proof of mechanism and support of dose finding, together with the safety evaluation in patients with clinical evidence of NASH. To gain further ...

A 5-year Longitudinal Observational Study of Patients With Nonalcoholic Fatty Liver Disease (NAFLD) or Nonalcoholic Steatohepatitis (NASH)

TARGET-NASH is a longitudinal observational cohort study of patients being managed for NAFLD or NASH in usual clinical practice. TARGET-NASH will create a research registry of patients wit...

Protocol for the Assessment of Variability in Histology and Gene Expression in Bariatric Surgery Patients.

It is known that a vast majority of patients seeking a bariatric surgery weight reduction procedure have non-alcoholic fatty liver disease (NAFLD), while a smaller subset of patients withi...

Safety, Tolerability, Pharmacokinetics and Efficacy of LMB763 in Patients With NASH

The purpose of the present study is to assess the effects of LMB763 with respect to safety, tolerability, and on markers of liver inflammation in patients with NASH

Companies [1683 Associated Companies listed on BioPortfolio]

HARVEY NASH GROUP

Harvey Nash was founded in London in 1988. David Higgins, the current Executive Vice Chairman, was one of the original founders and still has a sizeable financial stake in the company. Early on, the m...

Nash Finch Company

Patricia Nash

The quintessential embodiment of style, form and function, Patricia Nash Designs creates handbags and accessories that are made of beautiful, vegetable tanned Italian leather. The...

Harvey & Company LLC

Harvey & Company has a long track record of successful investments and acquisitions across a variety of manufacturing, business service and distribution sectors. Our success is based on the recognitio...

North American Specialty Hospital

Headquartered in Denver, NASH is a US majority-owned and managed enterprise. Incorporating US physicians in its service delivery, NASH is designed to provide pre-operative and pos...

More Information about "HARVEY NASH GROUP" on BioPortfolio

We have published hundreds of HARVEY NASH GROUP news stories on BioPortfolio along with dozens of HARVEY NASH GROUP Clinical Trials and PubMed Articles about HARVEY NASH GROUP for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of HARVEY NASH GROUP Companies in our database. You can also find out about relevant HARVEY NASH GROUP Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks



Searches Linking to this Company Record